Current and emerging molecular targets in glioma

Expert Review of Anticancer Therapy

Volumn 10, Issue 11, 2010, Pages 1735-1751

  Roesler, Rafael ^a,b,c   Brunetto, André T ^b   Abujamra, Ana Lucia ^a,b,c   De Farias, Caroline Brunetto ^a,b,c   Brunetto, Algemir Lunardi ^a,b,c   Schwartsmann, Gilberto ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

brain tumors; glioma; growth factor receptors; neuro oncology; neuropeptides; neurotrophins; protein kinase inhibitors; targeted therapy; therapeutic targets

Indexed keywords

AFLIBERCEPT; AMPA RECEPTOR ANTAGONIST; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; DIZOCILPINE; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE; NEUROTROPHIN; PROTEIN TYROSINE KINASE INHIBITOR; RC 3095; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VATALANIB;

BLEEDING; BRAIN CANCER; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; GLIOMA; HUMAN; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GLIOMA; HUMANS;

EID: 78649295690     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.167     Document Type: Review

References (196)

1. Louis DN, Ohgaki H, Wiestler OD. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2), 97-109 (2007). • Current criteria for the classification of brain tumors.
2. Carpentier AF. Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol. 4(1), 4-5 (2005).
3. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2(9), 494-503 (2006).
4. Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 359(5), 492-507 (2008).
5. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat. Rev. Drug Discov. 3(5), 430-446 (2004).
6. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). • Current standard of care for patients with newly diagnosed glioblastoma and potential markers predictive of response.
7. Minniti G, De Sanctis V, Muni R et al Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J. Neurooncol. 88(1), 97-103 (2008).
8. Brandes AA, Franceschi E, Tosoni A et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115(15), 3512-3518 (2009).
9. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5), 459-466 (2009).
10. Baer JC, Freeman AA, Newlands ES et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells. Br. J. Cancer 67(6), 1299-1302 (1993).
11. Brandes AA, Tosoni A, Cavallo G et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer 95(9), 1155-1160 (2006).
12. Wick A, Felsberg J, Steinbach JP et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol. 25(22), 3357-3361 (2007).
13. Neyns B, Chaskis C, Joosens E et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest. 26(3), 269-277 (2008).
14. Clarke JL, Iwamoto FM, Sul J et al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27(23), 3861-3867 (2009).
15. Perry JR, Belanger K, Mason WP et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28(12), 2051-2057 (2010).
16. Kong DS, Lee JI, Kim JH et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 12(3), 289-296 (2010).
17. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683-2710 (2007).
18. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 110(1), 13-24 (2007).
19. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2(87), re6 (2009).
20. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10(5), 319-331 (2010).
21. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
22. Castellino RC, Durden DL. Mechanisms of disease: the PI3K-AKT-PTEN signaling node - an intercept point for the control of angiogenesis in brain tumors. Nat. Clin. Pract. Neurol. 3, 682-693 (2007).
23. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci. Signal. 2(67), pe24 (2009).
24. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat. Rev. Cancer 7(7), 554-562 (2007).
25. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol. Res. 55(6), 477-486 (2007).
26. Mercer RW, Tyler MA, Ulasov IV, Lesniak MS. Targeted therapies for malignant glioma: progress and potential. BioDrugs 23(1), 25-35 (2009).
27. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008). • • Glioma was the first cancer studied by The Cancer Genome Atlas pilot project (TCGA). This paper reported the results of a genomic characterization of 206 glioblastomas performed by TCGA.
28. Shete S, Hosking FJ, Robertson LB et al. Genome-wide association study identifes five susceptibility loci for glioma. Nat. Genet. 41(8), 899-904 (2009). • Genome-wide association study that identifed five additional susceptibility loci for glioma.
29. Clark MJ, Homer N, O'Connor BD et al. U87MG decoded: the genomic sequence of a cy to genetically aberrant human cancer cell line. PLoS Genet. 6(1), e1000832 (2010). • Reports the first broad genome sequencing of a human glioma cell line.
30. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr. Opin. Oncol. 19(6), 598-605 (2007).
31. de Groot JF, Gilbert MR. New molecular targets in malignant gliomas. Curr. Opin. Neurol. 20(6), 712-718 (2007).
32. Sanson M. Editorial review: targets for glioma treatment: from bench to bedside. Curr. Opin. Oncol. 20(6), 650-651 (2008).
33. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 6(3), 500-512 (2009).
34. Iwamoto FM, Fine HA. Bevacizumab for malignant gliomas. Arch. Neurol. 67(3), 285-288 (2010).
35. Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr. Mol. Pharmacol. 3(1), 37-52 (2010).
36. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin. 60(3), 166-193 (2010).
37. Lieberman FS, Cloughesy T, Fine H et al. NABTC Phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J. Clin. Oncol. 22 (Suppl. 14) (2004) (Abstract 1510).
38. Rich JN, Reardon DA, Peery T et al. Phase II trial of geftinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133-142 (2004).
39. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/AKT, and glioma response to erlotinib. J. Natl Cancer Inst. 97(12), 880-887 (2005).
40. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17(8), 2572-2578 (1999).
41. van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27(8), 1268-1274 (2009).
42. Prados MD, Lamborn KR, Chang S et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 8(1), 67-78 (2006).
43. Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J. Clin. Oncol. 26(34), 5603-5609 (2008).
44. Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27(4), 579-584 (2009).
45. Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - Phase I/II trial: study protocol. BMC Cancer 6, 133(2006).
46. Raizer JJ, Abrey LE, Lassman AB et al. A Phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 12(1), 95-103 (2010).
47. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl. J. Med. 353(19), 2012-2024 (2005). • Broad discussion on the molecular determinants of the response of glioblastomas to EGF receptor kinase inhibitors.
48. Lassman AB, Rossi MR, Raizer JJ et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res. 11(21), 7841-7850 (2005).
49. Conrad C, Friedman H, Reardon D et al. A Phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. 22 (Suppl. 14) (2004) (Abstract 1512).
50. Reardon D, Friedman H, Yung WKA, et al. A Phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. 22 (Suppl. 14) (2004) (Abstract 1513).
51. De Groot JF, Wen PY, Lamborn K et al. Phase II single arm trial of afibercept in patients with recurrent temozolomideresistant glioblastoma: NABTC 0601. J. Clin. Oncol. 26 (Suppl. 15) (2008) (Abstract 2020).
52. Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel antiangiogenic agent in patients with glioblastoma. Expert Opin. Investig. Drugs 18(10), 1549-1557 (2009).
53. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
54. Brandes AA, Stupp R, Hau P et al. EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur. J. Cancer 46(2), 348-354 (2010).
55. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 12(6), 603-607 (2010).
56. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
57. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10), 779-787 (2008).
58. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
59. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
60. Lai A, Filka E, McGibbon B et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int. J. Radiat. Oncol. Biol. Phys. 71(5), 1372-1380 (2008).
61. Narayana A, Golfnos JG, Fischer I et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 72(2), 383-389 (2008).
62. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 15(14), 4589-4599 (2009).
63. Chamberlain MC, Raizer J. Antiangiogenic therapy for high-grade gliomas. CNS Neurol. Disord. Drug Targets 8(3), 184-194 (2009).
64. Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. 12(16), 4899-4907 (2006).
65. Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol. 26(28), 4659-4665 (2008).
66. Reardon DA, Desjardins A, Vredenburgh JJ et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. Neuro Oncol. 10(3), 330-340 (2008).
67. Dresemann G, Weller M, Rosenthal MA et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 96(3), 393-402 (2010).
68. Razis E, Selviaridis P, Labropoulos S et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin. Cancer Res. 15(19), 6258-6266 (2009).
69. Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23(4), 357-361 (2005).
70. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23(23), 5294-5304 (2005).
71. Cloughesy TF, Yoshimoto K, Nghiemphu P et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-defcient glioblastoma. PLoS Med. 5(1), e8 (2008).
72. Rao RD, Mladek AC, Lamont JD et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7(10), 921-929 (2005).
73. Reardon DA, Desjardins A, Vredenburgh JJ et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 96(2), 219-230 (2010).
74. Kreisl TN, Lassman AB, Mischel PS et al. A pilot study of everolimus and geftinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 92(1), 99-105 (2009).
75. Kreisl TN, Kotliarova S, Butman JA et al. A Phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 12(2), 181-189 (2010).
76. Fine HA, Puduvalli VK, Chamberlain MC et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): a Phase III study. J. Clin. Oncol. 26 (Suppl. 15) (2008) (Abstract 2005).
77. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010).
78. Tabatabai G, Frank B, Wick A et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann. Neurol. 61(2), 153-161 (2007).
79. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim. Biophys. Acta 1773(8), 1248-1255 (2007).
80. Cloughesy TF, Wen PY, Robins HI et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol. 24(22), 3651-3656 (2006).
81. Moyal EC, Laprie A, Delannes M et al. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 68(5), 1396-1401 (2007).
82. Gilbert MR, Gaupp P, Liu C et al. A Phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. J. Clin. Oncol. 24 (Suppl. 18) (2006) (Abstract 1556).
83. Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma. J. Clin. Oncol. 28 (Suppl. 15) (2010) (Abstract 2006).
84. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J. Clin. Oncol. 25(13), 1637-1638 (2007).
85. Ruegg C, Postigo AA, Sikorski EE, Butcher EC, Pytela R, Erle DJ. Role of integrin a 4 ß 7/a 4 ß P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J. Cell Biol. 117(1), 179-189 (1992).
86. Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610-5617 (2008).
87. Stupp R, Goldbrunner R, Neyns B et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 25 (Suppl. 18) (2007) (Abstract 2000).
88. Stupp R, Van Den Bent MJ, Erridge SC et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled Phase III trial (CENTRIC). J. Clin. Oncol. 28 (Suppl. 15) (2010) (Abstract TPS152).
89. Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20(13), 1563-1569 (2001).
90. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol. Metab. 13(3), 128-134 (2002).
91. Moody TW, Hill JM, Jensen RT. VIP as a trophic factor in the CNS and cancer cells. Peptides 24(1), 163-177 (2003).
92. Evers BM. Neurotensin and growth of normal and neoplastic tissues. Peptides 27(10), 2424-2433 (2006).
93. Patel O, Shulkes A, Baldwin GS. Gastrinreleasing peptide and cancer. Biochim. Biophys. Acta 1766(1), 23-41 (2006).
94. Cornelio D, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann. Oncol. 18(9), 1457-1466 (2007).
95. Dorsam RT, Gutkind JS. G-proteincoupled receptors and cancer. Nat. Rev. Cancer 7(2), 79-94 (2007).
96. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm. Metab. Res. 40(5), 315-322 (2008).
97. Moody TW, Merali Z. Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides 25(3), 511-520 (2004).
98. Roesler R, Henriques JA, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol. Disord. Drug Targets 5(2), 197-204 (2006).
99. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev. 60(1), 1-42 (2008). • • Comprehensive review of the involvement of bombesin-like peptides and their receptors in health and disease.
100. Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: new options for the therapy and diagnosis of cancer. Cell Cycle 9(9), 1738-1741 (2010).
101. Flores DG, Meurer L, Uberti AF et al. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res. Bull. 82 (1-2), 95-98 (2010).
102. Moody TW, Mahmoud S, Staley J et al. Human glioblastoma cell lines have neuropeptide receptors for bombesin/gastrin-releasing peptide. J. Mol. Neurosci. 1(4), 235-242 (1989).
103. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res. 54(22), 5895-5901 (1994).
104. Sharif TR, Luo W, Sharif M. Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol. Cell. Endocrinol. 130 (1-2), 119-130 (1997).
105. de Farias CB, Lima RC, Lima LO et al. Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling. Oncology 75 (1-2), 27-31 (2008).
106. Flores DG, de Farias CB, Leites J et al. Gastrin-releasing peptide receptors regulate proliferation of C6 glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism. Curr. Neurovasc. Res. 5(2), 99-105 (2008).
107. Flores DG, Lenz G, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor signaling in cancer. Cancer Ther. 7 (A), 332-346 (2009).
108. Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, Horvath JE. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proc. Natl Acad. Sci. USA 94(20), 10913-10918 (1997).
109. Kiaris H, Schally AV, Sun B, Armatis P, Groot K. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin- releasing peptide. Oncogene 18(50), 7168-7173 (1999).
110. Bajo AM, Schally AV, Krupa M, Hebert F, Groot K, Szepeshazi K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc. Natl Acad. Sci. USA 99(6), 3836-3841 (2002).
111. de Oliveira MS, Cechim G, Braganhol E et al. Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J. Neurooncol. 93(2), 191-201 (2009). • Preclinical study showing significant reduction of glioma growth in vivo after treatment with a gastrin-releasing peptide receptor antagonist combined with temozolomide.
112. Schwartsmann G, DiLeone LP, Horowitz M et al. A Phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest. New Drugs 24(5), 403-412 (2006).
113. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72, 609-642 (2003).
114. Hutton LA, deVellis J, Perez-Polo JR. Expression of p75NGFR TrkA, and TrkB mRNA in rat C6 glioma and type I astrocyte cultures. J. Neurosci. Res. 32(3), 375-383 (1992).
115. Spoerri PE, Romanello S, Petrelli L et al. Nerve growth factor (NGF) receptors in a central nervous system glial cell line: upregulation by NGF and brain-derived neurotrophic factor. J. Neurosci. Res. 33(1), 82-90 (1992).
116. Hamel W, Westphal M, Szönyi E, Escandón E, Nikolics K. Neurotrophin gene expression by cell lines derived from human gliomas. J. Neurosci. Res. 34(2), 147-157 (1993).
117. Chiaretti A, Aloe L, Antonelli A et al. Neurotrophic factor expression in childhood low-grade astrocytomas and ependymomas. Childs Nerv. Syst. 20(6), 412-419 (2004).
118. Grotzer MA, Janss AJ, Fung K et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J. Clin. Oncol. 18(5), 1027-1035 (2000).
119. Oelmann E, Sreter L, Schuller I et al. Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling. Cancer Res. 55(10), 2212-2219 (1995).
120. Singer HS, Hansen B, Martinie D, Karp CL. Mitogenesis in glioblastoma multiforme cell lines: a role for NGF and its TrkA receptors. J. Neurooncol. 45(1), 1-8 (1999).
121. Watanabe T, Katayama Y, Kimura S, Yoshino A. Control of proliferation and survival of C6 glioma cells with modification of the nerve growth factor autocrine system. J. Neurooncol. 41(2), 121-128 (1999).
122. Pflug BR, Colangelo AM, Tornatore C, Mocchetti I. TrkA induces differentiation but not apoptosis in C6-2B glioma cells. J. Neurosci. Res. 64(6), 636-645 (2001).
123. Kimura S, Yoshino A, Katayama Y, Watanabe T, Fukushima T. Growth control of C6 glioma in vivo by nerve growth factor. J. Neurooncol. 59(3), 199-205 (2002).
124. Weis C, Wiesenhofer B, Humpel C. Nerve growth factor plays a divergent role in mediating growth of rat C6 glioma cells via binding to the p75 neurotrophin receptor. J. Neurooncol. 56(1), 59-67 (2002).
125. Brown MC, Staniszewska I, Lazarovici P, Tuszynski GP, Del Valle L, Marcinkiewicz C. Regulatory effect of nerve growth factor in a9p1 integrin-dependent progression of glioblastoma. Neuro Oncol. 10(6), 968-980 (2008).
126. Spoerri PE, Romanello S, Petrelli L, Negro A, Guidolin D, Skaper SD. Neurotrophin-3 upregulates NGF receptors in a central nervous system glial cell line. Neuroreport 4(1), 33-36 (1993).
127. Meller R, Babity JM, Grahame-Smith DG. 5-HT2A receptor activation leads to increased BDNF mRNA expression in C6 glioma cells. Neuromolecular Med. 1(3), 197-205 (2002).
128. Calatozzolo C, Salmaggi A, Pollo B et al Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurol Sci. 28(6), 304-310 (2007).
129. Chin LS, Murray SF, Zitnay KM, Rami B. K252a inhibits proliferation of glioma cells by blocking platelet-derived growth factor signal transduction. Clin. Cancer Res. 3(5), 771-776 (1997).
130. Schmidt AL, de Farias CB, Abujamra AL et al. BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells. J. Mol. Neurosci. 40(3), 303-310 (2010).
131. Johnston AL, Lun X, Rahn JJ et al. The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol. 5(8), e212 (2007).
132. Wang L, Rahn JJ, Lun X et al. γ-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol. 6(11), e289 (2008).
133. Mayer ML. Glutamate receptor ion channels. Curr. Opin. Neurobiol. 15(3), 282-288 (2005).
134. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9(11), 984-997 (2004).
135. Nakazawa K, McHugh TJ, Wilson MA, Tonegawa S. NMDA receptors, place cells and hippocampal spatial memory. Nat. Rev. Neurosci. 5(5), 361-372 (2004).
136. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97(6), 1611-1626 (2006).
137. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 59(17), 4383-4391 (1999).
138. Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study J. Neurooncol. 47(1), 11-22 (2000).
139. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat. Med. 7(9), 1010-1015 (2001). • • Seminal preclinical study showing a role for glutamate in glioma growth and potential therapeutic effects of glutamate receptor antagonists in glioma.
140. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 67(19), 9463-9471 (2007).
141. Abdul M, Hoosein N. N-methyl-daspartate receptor in human prostate cancer. J. Membr. Biol. 205(3), 125-128 (2005).
142. Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro C, Nishizaki T The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem. Biophys. Res. Commun. 367(2), 487-490 (2008).
143. North WG, Gao G, Memoli VA, Pang RH, Lynch L. Breast cancer expresses functional NMDA receptors. Breast Cancer Res. Treat. 122(2), 307-314 (2010).
144. Kalariti N, Lembessis P, Koutsilieris M. Characterization of the glutamatergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res. 24(6), 3923-3929 (2004).
145. Choi SW, Park SY, Hong SP, Pai H, Choi JY, Kim SG. The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma. J. Oral Pathol. Med. 33(9), 533-537 (2004).
146. Rzeski W, Ikonomidou C, Turski L. Glutamate antagonists limit tumor growth. Biochem. Pharmacol. 64(8), 1195-1200 (2002).
147. Stepulak A, Sifringer M, Rzeski W et al NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc. Natl Acad. Sci. USA 102(43), 15605-15610 (2005).
148. Ishiuchi S, Tsuzuki K, Yoshida Y et al. Blockage of Ca (2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med. 8(9), 971-978 (2002).
149. Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via ß1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 11(3), 260-273 (2009).
150. van Vuurden DG, Yazdani M, Bosma I et al. Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. PLoS One 4(6), e5953 (2009).
151. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D. Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol. Sci. 28(5), 206-213 (2007).
152. Iwamoto FM, Kreisl TN, Kim L et al. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 116(7), 1776-1782 (2010).
153. Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol. 27(25), 4155-4161 (2009).
154. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14(3), 737-744 (1996).
155. Schwechheimer K, Läufe RM, Schmahl W, Knödlseder M, Fischer H, Höfer H. Expression of neu/c-erbB-2 in human brain tumors. Hum. Pathol. 25(8), 772-780 (1994).
156. Kristt DA, Yarden Y. Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes. Implications for glial oncogenesis. Cancer 78(6), 1272-1283 (1996).
157. Koka V, Potti A, Forseen SE et al. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am. J. Clin. Oncol. 26(4), 332-335 (2003).
158. Mineo JF, Bordron A, Baroncini M et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J. Neurooncol. 85(3), 281-287 (2007).
159. Haynik DM, Roma AA, Prayson RA. HER-2/neu expression in glioblastoma multiforme. Appl. Immunohistochem. Mol. Morphol. 15(1), 56-58 (2007).
160. ®) induces cellular death of glioblastomas. Br. J. Cancer 91(6), 1195-1199 (2004).
161. Thiessen B, Stewart C, Tsao M et al. A Phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother. Pharmacol. 65(2), 353-361 (2009).
162. Furman MA, Shulman K. Cyclic AMP and adenyl cyclase in brain tumors. J. Neurosurg. 46(4), 477-483 (1977).
163. Chen TC, Hinton DR, Zidovetzki R, Hofman FM. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab. Invest. 78(2), 165-174 (1998).
164. Chen TC, Wadsten P, Su S et al. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21 (Cip1) and p27 (Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol. Ther. 1(3), 268-276 (2002).
165. Helmbrecht K, Rensing L. Different constitutive heat shock protein 70 expression during proliferation and differentiation of rat C6 glioma cells. Neurochem. Res. 24(1), 1293-1299 (1999).
166. Goldhoff P, Warrington NM, Limbrick DD Jr et al. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin. Cancer Res. 14(23), 7717-7725 (2008).
167. Schmidt AL, de Farias CB, Abujamra AL, Brunetto AL, Schwartsmann G, Roesler R. Phosphodiesterase-4 inhibition and brain tumor growth. Clin. Cancer Res. 15(9), 3238(2009).
168. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Ver. Cancer 6(1), 38-51 (2006).
169. Burgess R, Jenkins R, Zhang Z. Epigenetic changes in gliomas. Cancer Biol. Ther. 7(9), 1326-1334 (2008).
170. Nagarajan R P, Costello JF. Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 6(3), 436-446 (2009).
171. Kamitani H, Taniura S, Watanabe K, Sakamoto M, Watanabe T, Eling T. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. Neuro Oncol. 4(2), 95-101 (2002).
172. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63(21), 7291-7300 (2003).
173. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1174-1180 (2004).
174. Sawa H, Murakami H, Kumagai M et al Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 107(6), 523-531 (2004).
175. Entin-Meer M, Rephaeli A, Yang X, Nudelman A, Van den Berg SR, Haas-Kogan DA. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol. Cancer Ther. 4(12), 1952-1961 (2005).
176. Komata T, Kanzawa T, Nashimoto T et al Histone deacetylase inhibitors, N-butyric acid and trichostatin A, induce caspase-8-but not caspase-9-dependent apoptosis in human malignant glioma cells. Int. J. Oncol. 26(5), 1345-1352 (2005).
177. Wetzel M, Premkumar DR, Arnold B, Pollack IF. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J. Neurosurg. 103 (6 Suppl.), 549-556 (2005).
178. Das CM, Aguilera D, Vasquez H et al Valproic acid induces p21 and topoisomerase-II (a/ß) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J. Neurooncol. 85(2), 159-170 (2007).
179. Masoudi A, Elopre M, Amini E et al Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 28 (4C), 2437-2442 (2008). • • One of the first clinical trials of valproic acid in glioma.
180. Wolff JE, Kramm C, Kortmann RD et al Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J. Neurooncol. 90(3), 309-314 (2008).
181. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J. Clin. Oncol. 27(12), 2052-2058 (2009).
182. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003).
183. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432(7015), 396-401 (2004). • • First study demonstrating that brain tumor stem cells can initiate tumor formation in vivo.
184. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat. Clin. Pract. Neurol. 4(8), 427-435 (2008).
185. Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J. Biol. Chem. 284(25), 16705-16709 (2009).
186. Flores DG, Ledur PF, Abujamra AL et al. Cancer stem cells and the biology of brain tumors. Curr. Stem Cell Res. Ther. 4(4), 306-313 (2009).
187. Roesler R, Cornelio DB, Abujamra AL, Schwartsmann G. HER2 as a cancer stem-cell target. Lancet Oncol. 11(3), 225-226 (2010).
188. Groves MD, Puduvalli VK, Gilbert MR et al. Two Phase II trials of temozolomide with interferon-a2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br. J. Cancer 101(4), 615-620 (2009).
189. Tentori L, Leonetti C, Scarsella M et al. Systemic administration of GPI 15427, a novel poly (ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 9(14), 5370-5379 (2003).
190. Zheng H, Ying H, Wiedemeyer R et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 17(5), 497-509 (2010). • Very elegant recent study identifying a novel oncogene in glioma.
191. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848), 287-290 (2007).
192. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8(7), 1277-1280 (1990).
193. Sawlani RN, Raizer J, Horowitz SW et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging - pilot study. Radiology 255(2), 622-628 (2010).
194. Chang SM, Lamborn KR, Kuhn JG et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 10(4), 631-642 (2008). • • Key elements to ensure the success of an integrated approach to conduct early clinical trials in neuro-oncology are discussed.
195. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5(2), 160-170 (2006).
196. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39(3), 347-351 (2007). • High-throughput genotyping of 238 known oncogene mutations across 1000 human tumor samples.